These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

225 related items for PubMed ID: 24957256

  • 1. Health utility of patients with advanced gastrointestinal stromal tumors (GIST) after failure of imatinib and sunitinib: findings from GRID, a randomized, double-blind, placebo-controlled phase III study of regorafenib versus placebo.
    Poole CD, Connolly MP, Chang J, Currie CJ.
    Gastric Cancer; 2015 Jul; 18(3):627-34. PubMed ID: 24957256
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Efficacy and Safety of Regorafenib in Korean Patients with Advanced Gastrointestinal Stromal Tumor after Failure of Imatinib and Sunitinib: A Multicenter Study Based on the Management Access Program.
    Son MK, Ryu MH, Park JO, Im SA, Kim TY, Lee SJ, Ryoo BY, Park SR, Kang YK.
    Cancer Res Treat; 2017 Apr; 49(2):350-357. PubMed ID: 27456941
    [Abstract] [Full Text] [Related]

  • 4. Regorafenib for advanced gastrointestinal stromal tumors following imatinib and sunitinib treatment: a subgroup analysis evaluating Japanese patients in the phase III GRID trial.
    Komatsu Y, Doi T, Sawaki A, Kanda T, Yamada Y, Kuss I, Demetri GD, Nishida T.
    Int J Clin Oncol; 2015 Oct; 20(5):905-12. PubMed ID: 25655899
    [Abstract] [Full Text] [Related]

  • 5. Efficacy and safety of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of imatinib and sunitinib: a multicenter phase II trial.
    George S, Wang Q, Heinrich MC, Corless CL, Zhu M, Butrynski JE, Morgan JA, Wagner AJ, Choy E, Tap WD, Yap JT, Van den Abbeele AD, Manola JB, Solomon SM, Fletcher JA, von Mehren M, Demetri GD.
    J Clin Oncol; 2012 Jul 01; 30(19):2401-7. PubMed ID: 22614970
    [Abstract] [Full Text] [Related]

  • 6. Comparison of performance of various tumour response criteria in assessment of regorafenib activity in advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib.
    Shinagare AB, Jagannathan JP, Kurra V, Urban T, Manola J, Choy E, Demetri GD, George S, Ramaiya NH.
    Eur J Cancer; 2014 Mar 01; 50(5):981-6. PubMed ID: 24388774
    [Abstract] [Full Text] [Related]

  • 7. Phase II Trial of Continuous Regorafenib Dosing in Patients with Gastrointestinal Stromal Tumors After Failure of Imatinib and Sunitinib.
    Kim JJ, Ryu MH, Yoo C, Beck MY, Ma JE, Kang YK.
    Oncologist; 2019 Nov 01; 24(11):e1212-e1218. PubMed ID: 31036770
    [Abstract] [Full Text] [Related]

  • 8. Long-term follow-up results of the multicenter phase II trial of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of standard tyrosine kinase inhibitor therapy.
    Ben-Ami E, Barysauskas CM, von Mehren M, Heinrich MC, Corless CL, Butrynski JE, Morgan JA, Wagner AJ, Choy E, Yap JT, Van den Abbeele AD, Solomon SM, Fletcher JA, Demetri GD, George S.
    Ann Oncol; 2016 Sep 01; 27(9):1794-9. PubMed ID: 27371698
    [Abstract] [Full Text] [Related]

  • 9. Pazopanib plus best supportive care versus best supportive care alone in advanced gastrointestinal stromal tumours resistant to imatinib and sunitinib (PAZOGIST): a randomised, multicentre, open-label phase 2 trial.
    Mir O, Cropet C, Toulmonde M, Cesne AL, Molimard M, Bompas E, Cassier P, Ray-Coquard I, Rios M, Adenis A, Italiano A, Bouché O, Chauzit E, Duffaud F, Bertucci F, Isambert N, Gautier J, Blay JY, Pérol D, PAZOGIST study group of the French Sarcoma Groupe-Groupe d'Etude des Tumeurs Osseuses (GSF-GETO).
    Lancet Oncol; 2016 May 01; 17(5):632-41. PubMed ID: 27068858
    [Abstract] [Full Text] [Related]

  • 10. A phase II trial of regorafenib in patients with metastatic and/or a unresectable gastrointestinal stromal tumor harboring secondary mutations of exon 17.
    Yeh CN, Chen MH, Chen YY, Yang CY, Yen CC, Tzen CY, Chen LT, Chen JS.
    Oncotarget; 2017 Jul 04; 8(27):44121-44130. PubMed ID: 28487491
    [Abstract] [Full Text] [Related]

  • 11. ESMO: regorafenib improved PFS for GIST in post-imatinib/sunitinib setting.
    Oncology (Williston Park); 2012 Nov 04; 26(11):1072. PubMed ID: 23330348
    [No Abstract] [Full Text] [Related]

  • 12. Resumption of imatinib to control metastatic or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib (RIGHT): a randomised, placebo-controlled, phase 3 trial.
    Kang YK, Ryu MH, Yoo C, Ryoo BY, Kim HJ, Lee JJ, Nam BH, Ramaiya N, Jagannathan J, Demetri GD.
    Lancet Oncol; 2013 Nov 04; 14(12):1175-82. PubMed ID: 24140183
    [Abstract] [Full Text] [Related]

  • 13. Phase I Study of Rapid Alternation of Sunitinib and Regorafenib for the Treatment of Tyrosine Kinase Inhibitor Refractory Gastrointestinal Stromal Tumors.
    Serrano C, Leal A, Kuang Y, Morgan JA, Barysauskas CM, Phallen J, Triplett O, Mariño-Enríquez A, Wagner AJ, Demetri GD, Velculescu VE, Paweletz CP, Fletcher JA, George S.
    Clin Cancer Res; 2019 Dec 15; 25(24):7287-7293. PubMed ID: 31471313
    [Abstract] [Full Text] [Related]

  • 14. [A case of a gastrointestinal stromal tumor of the rectum effectively treated with continuously-administered regorafenib after failure of imatinib and sunitinib].
    Kajiura S, Hosokawa A, Nanjyo S, Nakada N, Ando T, Sugiyama T.
    Nihon Shokakibyo Gakkai Zasshi; 2016 Apr 15; 113(4):655-61. PubMed ID: 27052395
    [Abstract] [Full Text] [Related]

  • 15. Regorafenib in gastrointestinal stromal tumors.
    Sirohi B, Philip DS, Shrikhande SV.
    Future Oncol; 2014 Apr 15; 10(9):1581-7. PubMed ID: 25145429
    [Abstract] [Full Text] [Related]

  • 16. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumor after failure with imatinib and sunitinib treatment: A meta-analysis.
    Zhang Z, Jiang T, Wang W, Piao D.
    Medicine (Baltimore); 2017 Dec 15; 96(48):e8698. PubMed ID: 29310342
    [Abstract] [Full Text] [Related]

  • 17. The safety of regorafenib for the treatment of gastrointestinal stromal tumors.
    Rutkowski P, Stępniak J.
    Expert Opin Drug Saf; 2016 Jan 15; 15(1):105-16. PubMed ID: 26651387
    [Abstract] [Full Text] [Related]

  • 18. Regorafenib: a novel multitargeted tyrosine kinase inhibitor for colorectal cancer and gastrointestinal stromal tumors.
    Crona DJ, Keisler MD, Walko CM.
    Ann Pharmacother; 2013 Dec 15; 47(12):1685-96. PubMed ID: 24259629
    [Abstract] [Full Text] [Related]

  • 19. Tyrosine kinase inhibitors in the treatment of unresectable or metastatic gastrointestinal stromal tumors.
    Nishida T, Doi T, Naito Y.
    Expert Opin Pharmacother; 2014 Oct 15; 15(14):1979-89. PubMed ID: 24990162
    [Abstract] [Full Text] [Related]

  • 20. Efficacy and safety of regorafenib in adult patients with metastatic osteosarcoma: a non-comparative, randomised, double-blind, placebo-controlled, phase 2 study.
    Duffaud F, Mir O, Boudou-Rouquette P, Piperno-Neumann S, Penel N, Bompas E, Delcambre C, Kalbacher E, Italiano A, Collard O, Chevreau C, Saada E, Isambert N, Delaye J, Schiffler C, Bouvier C, Vidal V, Chabaud S, Blay JY, French Sarcoma Group.
    Lancet Oncol; 2019 Jan 15; 20(1):120-133. PubMed ID: 30477937
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.